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Abstract
Background: Cardiac contractility is regulated by dynamic phosphorylation of sarcomeric proteins by kinases such
as cAMP-activated protein kinase A (PKA). Efficient phosphorylation requires that PKA be anchored close to its
targets by A-kinase anchoring proteins (AKAPs). Cardiac Myosin Binding Protein-C (cMyBPC) and cardiac troponin I
(cTNI) are hypertrophic cardiomyopathy (HCM)-causing sarcomeric proteins which regulate contractility in response
to PKA phosphorylation.
Results: During a yeast 2-hybrid (Y2H) library screen using a trisphosphorylation mimic of the C1-C2 region of
cMyBPC, we identified isoform 4 of myomegalin (MMGL) as an interactor of this N-terminal cMyBPC region. As
MMGL has previously been shown to interact with phosphodiesterase 4D, we speculated that it may be a PKA-
anchoring protein (AKAP).
To investigate this possibility, we assessed the ability of MMGL isoform 4 to interact with PKA regulatory subunits
R1A and R2A using Y2H-based direct protein-protein interaction assays. Additionally, to further elucidate the
function of MMGL, we used it as bait to screen a cardiac cDNA library. Other PKA targets, viz. CARP, COMMD4,
ENO1, ENO3 and cTNI were identified as putative interactors, with cTNI being the most frequent interactor.
We further assessed and confirmed these interactions by fluorescent 3D-co-localization in differentiated H9C2 cells
as well as by in vivo co-immunoprecipitation. We also showed that quantitatively more interaction occurs between
MMGL and cTNI under b-adrenergic stress. Moreover, siRNA-mediated knockdown of MMGL leads to reduction of
cMyBPC levels under conditions of adrenergic stress, indicating that MMGL-assisted phosphorylation is requisite for
protection of cMyBPC against proteolytic cleavage.
Conclusions: This study ascribes a novel function to MMGL isoform 4: it meets all criteria for classification as an
AKAP, and we show that is involved in the phosphorylation of cMyBPC as well as cTNI, hence MMGL is an
important regulator of cardiac contractility. This has further implications for understanding the patho-aetiology of
HCM-causing mutations in the genes encoding cMyBPC and cTNI, and raises the question of whether MMGL might
itself be considered a candidate HCM-causing or modifying factor.
Background
Cardiac contractility is significantly enhanced by the
dynamic phosphorylation of a number of sarcomeric
proteins, including cardiac myosin binding protein C
(cMyBPC) [1,2]. This highly modular protein, found in
the C-zone of the sarcomere, is encoded by a gene
which is frequently implicated in hypertrophic cardio-
myopathy (HCM) [3], a common inherited cardiac dis-
ease characterised by hypertrophy of the ventricular
muscle [4]. There are multiple isoforms of this protein;
the cardiac isoform differs from its skeletal counterparts
by containing an extra immunoglobulin-like (IgI)
domain (C0) at the amino terminal, a charged residue-
rich insertion in domain C5 and three phosphorylation
sites in a motif between the second and third IgI
domains (C1-C2), known as the MyBPC motif or m-
* Correspondence: hm@sun.ac.za
1US/MRC Centre for Molecular and Cellular Biology, Department of
Biomedical Sciences, University of Stellenbosch, South Africa
Full list of author information is available at the end of the article
Uys et al. BMC Cell Biology 2011, 12:18
http://www.biomedcentral.com/1471-2121/12/18
© 2011 Uys et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.domain. Originally thought to have only a structural
role, cMyBPC has been shown to play an important role
in the regulation of cardiac contractility [1], for which
the N-terminal region of the protein appears to be cru-
cial. Upon b-adrenergic stimulation, three sites within
the MyBPC motif are phosphorylated by protein kinase
A (PKA) and calcium/calmodulin-activated protein
kinase (CaMK), the phosphorylation of this region of
MyBPC then leads to rearrangement of the myosin
crossbridges and thick filament structure [1,5,6] such
that cardiac contractility is increased [7].
However, since these kinases regulate a broad range of
cellular responses, their compartmentalization in close
proximity to their sarcomeric targets is required to facil-
itate control over which proteins are phosphorylated in
response to second messenger signalling [8,9]. At the
same time, co-compartmentalization of enzymes or pro-
teins that generate or terminate these second messenger
metabolites, such as the phosphodiesterases (PDEs)
which degrade cAMP and cGMP, with the relevant
responsive kinases helps to optimise the precision and
speed of response to second messenger signaling [10].
Compartmentalization of kinases in general is achieved
by either direct docking of the kinase on the target pro-
t e i n ,o rb ya n c h o r i n go ft h ek i n a s et o ,o rc l o s et o ,t h e
target via an adaptor protein, named A-kinase anchoring
proteins or AKAPs in the case of PKA [11]. Although a
CaMK has been found to co-purify with cMyBPC [1,12],
the mechanism of co-compartmentalization of cMyBPC
and PKA has never been described and very little is
known about sarcomeric AKAPs in general.
In this study we identified myomegalin (MMGL) iso-
form 4, a PDE4D-interacting protein [13], as a binding
partner of PKA, the cMyBPC N-terminal region, as well
as other PKA-targets, and show that MMGL meets all
the requirements for classification as a novel sarcomeric
AKAP, with important implications for regulation of
cardiac contractility during adrenergic stimulation.
Results
Interaction of trisphospho-cMyBPC with MMGL
As the interactions of the N-terminal region of cMyBPC
under its various phosphorylation states appear to be
integral to the regulatory role of cMyBPC in contracti-
lity, we aimed to gain further insight into the interac-
tions of the trisphosphorylated form of the N-terminal
region of cMyBPC. Thus, we used a construct of C1-C2
in which the serines in the three phosphorylation sites
of the MyBPC motif had been replaced by glutamic
acids (PPP), mimicking the trisphosphorylated state, as
bait in a Y2H cardiac library screen.
During successive rounds of nutritional and colori-
metric selection, 19 putative interactors of PPP were
identified, which were able to activate the HIS3, ADE2
and MEL1 reporter genes in the presence of the PPP
bait, but not in the presence of heterologous baits
(Table 1). Of these, three in-frame prey plasmids
encoded isoform 4 of PDE4D-interacting protein, also
known as myomegalin (MMGL) (Table 1). This putative
interaction between MMGL and the N-terminal of
cMyBPC was intriguing, as the former protein is known
to anchor PDE4D to particulate structures; PDE4D, in
turn, is known to hydrolyze cAMP and thus to attenuate
PKA-driven phosphorylation [13]. Furthermore, it has
been shown that some adaptor proteins can anchor
both PKA and PDE4D [14], raising the possibility that
MMGL may be anchoring PKA to at least cMyBPC in
the sarcomere as an AKAP; hence this interaction was
prioritized for further investigation.
3D-fluorescence microscopy indicated that cMyBPC
and MMGL isoform 4 colocalize in the cytoplasmic
(encompassing the sarcomeric) region of differentiated
rat cardiac H9C2 cells (Figure 1A). Exposure of the cells
to the adrenergic agonist isoproterenol led to an
increase in co-localization of the two proteins, as evi-
denced by the increased yellow staining during fluores-
cence microscopy of such cells (Figure 1B, C).
Furthermore, in order to verify that it is the C1-C2
region of cMyBPC that interacts with MMGL isoform 4,
specifically, and does so in the absence of the GAL4
regions of the Y2H bait protein, we used in vitro co-
immunoprecipitation assays. We also used these assays
to assess whether trisphosphorylation of the MyBPC
motif within this region was crucial to the putative
interaction. Both the native C1-C2 and a trisphospho-
mimic of the C1-C2 region interacted with MMGL iso-
form 4 in the absence of the Y2H GAL4 domains
(Figure 2A), suggesting that the interaction can take
place whether or not the MyBPC-motif is phosphory-
lated. Interaction between cMyBPC and MMGL isoform
4 was further confirmed in a cellular environment by
reciprocal co-immunoprecipitation of these tagged pro-
teins in H9C2 cells (Figure 2B).
MMGL binds to PKA regulatory subunits
As the primary characteristic of an AKAP is the ability
to bind at least one PKA regulatory subunit, we inves-
tigated the possibility that MMGL functions as an
AKAP by using Y2H-based direct protein-protein
interaction assays to determine binding between
MMGL and the two cardiac-expressed regulatory sub-
units of PKA. Both regulatory subunits (PRKAR1A and
PRKAR2A) interacted with MMGL, as assessed by
growth and light colour of the colonies on quadruple
dropout nutritional selection medium, compared to
relevant controls (Figure 3A).
Further support for this finding was garnered by co-
localization studies using 3D-fluorescence microscopy:
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Page 2 of 15we demonstrated that MMGL isoform 4 occurs in the
same 3D-subcellular region as the two PKA regulatory
isoforms in H9C2 cardiomyocytes (Figure 3B).
To further verify physical interaction between MMGL
and these PKA isoforms in a cellular context and in the
absence of GAL4 domains, we performed pull-down
assays in differentiated H9C2 cardiomyocytes. As com-
mercial antibodies against MMGL/PDE4DIP are not
able to detect isoform 4, the smallest isoform of this
protein, we used an antibody directed against dsRed to
detect a dsRed-tagged version of MMGL isoform 4 in
these assays. In this way, endogenous PRKAR1A and
PRKAR2A were shown to immunoprecipitate dsRed-
MMGL, and vice versa (Figure 3C), indicating physical
interaction of MMGL with these two PKA regulatory
isoforms.
MMGL binds to additional PKA targets
We further investigated the function of MMGL isoform
4 by using it as Y2H bait to screen a cardiac cDNA
library in order to identify its additional binding part-
ners. Thirteen in-frame putative MMGL-interactors
were identified that activated all three nutritional repor-
ter genes in the presence of the MMGL bait, but not in
t h ep r e s e n c eo fh e t e r o l o g ous baits (Table 2). As we
were primarily interested in the possibility of MMGL
acting as a sarcomeric AKAP, proteins with defined
vesicular localizations were not considered of primary
interest for follow-up in this study; these included the
mitochondrial protein COX5A, the proteosome 26S
subunit and the endosomal protein SNX3. Of the
remaining ten putative MMGL interactors, six encoded
cardiac troponin I (cTNI) (Table 2).
Further support for the validity of these interactions
was provided by finding that MMGL occurs in the same
3D-subcellular region as all five of the putative interac-
tors identified in the Y2H library screen, viz. cardiac
ankyrin repeat protein (CARP), copper metabolism gene
MURR1 domain 4 (COMMD4), a-enolase (ENO1), b-
enolase (ENO3) (Figure 4), and cardiac troponin I
(cTNI) (Figure 5), in differentiated cardiomyocytes.
Moreover, in pull-down assays, exogenous, fluores-
cently-tagged MMGL and endogenous ENO1, ENO3,
CARP and cTNI reciprocally co-precipitated each other
(Figure 6i-iv). As COMMD4 had a similar mobility to
antibody light chains, which interfered with detection of
these proteins in Western blots, a GFP-tagged fusion of
this protein was expressed in H9C2 cells for pull-down
assays. In these assays, exogenous GFP-COMMD4
immunoprecipitated exogenous dsRed-MMGL, and vice
versa (Figure 6v). Thus, Western blot analysis data sup-
ported the proposed interaction of MMGL with ENO1,
ENO3, CARP, cTNI and COMMD4.
cTNI is a known PKA target [15], while the remaining
four putative interactors were shown to be likely targets
using Phosphomotif Finder http://www.hprd.org/Phos-
phoMotif_finder; we therefore investigated the effect of
isoproterenol stimulation of the H9C2 cells on co-locali-
zation, using the most frequent, and sarcomeric-located,
putative interactor, cTNI, as example. Treating H9C2
Table 1 Interactors of the C1-C2 region of cMyBPC in the trisphospho-mimic state as identified by yeast 2-hybrid
library screening
Clone # Genomic Hit, Accession no
(E-value)
In-frame ORF Protein Hit, Accession no (E-value) Subcellular localization
P205, P272,
P403
PDE4DIP, transcript 4
NM_001002810 (0.0)
Homo sapiens phosphodiesterase 4D interacting protein
(myomegalin) NP_055459.3 (1e-70)
Cytoplasm, Cytoskeleton
P182, P286,
P267
ACTC1 NM_005159 (0.0) Homo sapiens actin, alpha, cardiac muscle 1 NP_005150 (1e-89) Thin filament sarcomere
P259 ACTCB NM_001101 (0.0) Homo sapiens actin, beta AAH23548.1 (8e-34) Cytoplasm, cytoskeleton
P62, P213,
P319
MYBPC3 NM_000256 (0.0) Homo sapiens cardiac myosin binding protein C, NP_000247.2 (2e-
26)
Thick filament; Sarcomere
P2,P81 Gcom1 transcript 12
NM_001018100 (0.0)
Homo sapiens GRINL1A combined protein NP_001018100.1, (2e-65) Unknown
P80 FLNC NM_001458.2 (0.0) Homo sapiens filamin C, gamma NP_001449.3 (2e-91) Myofibrillar z-disks; actin
cytoskeleton
P175, P465 CNN1 NM_001299.4 (0.0) Homo sapiens calponin 1, basic, smooth muscle NP_001290.2 (1e-
104)
Cytoplasm, cytoskeleton
P11 PARD3 NM_019619.2 (3e-121) Homo sapiens par-3 partitioning defective 3 homolog
NP_062565.2 (1e-24)
Plasma membrane; tight junctions
P223 CCT7 NM_001009570.1 (0.0) Homo sapiens chaperonin containing TCP1, subunit 7 (eta)
NP_001009570.1 (1e-83)
Cytoplasm
P238 SVIL NM_021738.1 (0.0) Homo sapiens supervillin NP_003165.1 (1e-15) Actin cytoskeleton, plasma
membrane, nucleus
P398 FLJ21347 NM_022827.2 (0.0) FLJ21347 NP_073738.2 (4e-101) Unknown
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Figure 1 MMGL isoform 4 interacts witht h eC 1 - C 2r e g i o no fc M y B P C . A. Representative image of live cell fluorescence microscopy
showing co-localization of cMyBPC and MMGL isoform 4. Each panel represents a single frame of the 25 images that were captured for the
vertical Z-stack. The first four panels shows a single colour channel, while the image in the last panel shows an overlay of the four colour
channels used. Column (iii) shows co-localization (yellow fluorescence) between dsRed-MMGL and GFP-cMyBPC, while column (iv) shows cardiac
actin, a marker of the sarcomeric region. Scale bar: 0.02 mm. B. Representative image of live cell fluorescence microscopy showing that co-
localization of MMGL isoform 4 and cMyBPC increases under adrenergic stress. Each panel represents a single frame of the 25 images that were
captured for the vertical Z-stack. Each of the first three columns shows a single colour channel, while the image in the last column shows an
overlay of the four colour channels used. Column (iii) shows co-localization (yellow fluorescence) between dsRed-MMGL and GFP-cMyBPC in the
absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. As evidenced by the increased yellow staining, co-
localization levels between MMGL and cMyBPC increased ten minutes after the addition of isoproterenol. Scale bar: 0.02 mm. C. Quantification of
co-localization shown in B demonstrates the significant increase in co-localization after the addition of isoproterenol (± SEM, *p < 0.05, n = 5).
Change in co-localization was calculated using the CellR software and presented as a false colour image and percent co-localization as described
by Loos et al., 2008 [29]. Abbreviations: isopro = isoproterenol
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Page 4 of 15cells transfected with dsRed-MMGL/GFP-cTNI with
isoproterenol resulted in significantly more 3D co-locali-
zation between these two prot e i n s ,a ss h o w ni nF i g u r e
5B and 5C, compared to non-treated cells.
Thus, our results strongly suggest that MMGL inter-
acts with both PKA regulatory isoforms, as well as with
each of the prioritized five putative prey interactors
identified in the Y2H screen, in a cellular milieu, and in
the absence of the GAL4 domains.
Effect of MMGL knockdown
In order to evaluate the role of MMGL in cMyBPC
phosphorylation, we assessed the expression of the dif-
ferent phosphorylation isoforms of cMyBPC, in the
A) 13 24 56
Proteins added:
35S-Myc-C1-C2
35S M C1 C2
30kD
35S-HA-MMGL
+ +
35S-Myc-PPP
35S-HA-MMGL
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-- +
++ -
-
-
-+ + anti-Myc +
IP:
- + - +
+
+
-
-
+
-
++
IP: dsRed JL8 HA
+- -
y
anti-HA -- -
B) WB: JL8 JL8 JL8
250kD
135kD
JL8
dsRed
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dsRed
HA
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IP:
WB:
72kD
95kD
52kD
Figure 2 Co-immunoprecipitations of MMGL isoform 4 and the C1-C2 region of cMyBPC. A. In vitro co-immunoprecipitation showing that
MMGL interacts with the native as well as the trisphospho-mimic of C1-C2 in the absence of Y2H GAL4 domains. B. In vivo co-
immunoprecipitation, showing that dsRed-tagged MMGL is able to specifically pull down GFP-cMyBPC, and vice versa, in H9C2 cells.
Abbreviations: JL8 = antibody directed against GFP, dsRed = antibody directed against dsRed-tagged proteins, HA = antibody directed against
haemaglutinin protein, used as negative control antibody, IP = antibody used in immunoprecipitation, WB = antibody used in western blotting.
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Figure 3 MMGL acts as a dual-specific AKAP by anchoring PKA regulatory isoforms R1A and R2A. A. Activation of nutritional reporter
genes by PKA-MMGL interaction during direct protein-protein interaction assays. Small-scale Y2H matings between pGBKT7-MMGL and pACT2-
PRKAR1A (i) and pACT2-PRKAR2A (ii) on solid medium lacking Leu, Trp, His and Ade. Growth of yeast yells indicate interaction of MMGL with
PRKAR1A as well as PRKAR2A. B. Representative images of live cell fluorescence microscopy showing co-localization of MMGL with PRKAR1A and
PRKAR2A in differentiated H9C2 cardiomyocytes. (i) GFP-tagged PRKAR1A and PRKAR2A is seen in the cytosol as green fluorescence. (ii) dsRed-
tagged MMGL expression is seen as red fluorescence. (iii) Yellow fluorescence indicates the co-localization of PRKAR1A and PRKAR2A with MMGL.
(iv) Overlay of images A-C with Hoechst H-33342 labelling of the nuclei (blue fluorescence), for orientation purposes. Scale bar: 0.02 mm. C.
Western blots of in vivo co-immunoprecipitations of PKA regulatory subunits and MMGL; the antibodies used in immunoprecipitation (IP) and
Western Blot (WB) are shown above each lane. Endogenous PRKAR1A and PRKAR2A immunoprecipitated exogenous dsRed-MMGL in lysates of
dsRed-MMGL-transfected, differentiated H9C2 cardiomyocytes. Conversely, PRKAR1A and PRKAR2A also immunoprecipitated exogenous dsRed-
MMGL in these lysates. The negative control lanes included lysates from cells not transfected with dsRed-MMGL, showing that these
precipitations are not spurious, but are the result of physical association between the relevant proteins. Abbreviations: Prot G = protein G control;
R1A = PRKAR1A; R2A = PRKAR2A, UT/- = negative control lanes.
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Page 6 of 15Table 2 Interactors of MMGL isoform 4 identified by yeast 2-hybrid library screening
Clone # Genomic Hit, Accession no & E-
value
In-frame ORF Protein Hit, Accession no & E-value Subcellular
localization
128, 137, 148, 149, 160,
200
TNNI3 NM 000363, 0.0 Homo sapiens troponin I type 3 (cardiac) NP 000354.3, 2e-
82
Thin filament
192 CARP NM 014391, 0.0 Homo sapiens Cardiac ankyrin repeat protein NP 055206,
2e-121
Cytosol, nucleus
715 COMMD4 NM 017828, 0.0 Homo sapiens COMM domain containing 4 NP 060298.2,
3e-97
Cytoplasm
130 ENO1 NM 001428, 0.0 Homo sapiens Enolase 1 (alpha) NP 001419, 4e-116 Cytoplasm
203 ENO3 NM 053013, 0.0 Homo sapiens Enolase 3 (beta, muscle) NP 001967.1, 000.1 Cytoplasm
i)G F Ptagged
iv.) Overlay 
with Hoechst-
ti d li iii ) C ll i t i ii ) dsRed MMGL i.) GFP-tagged stained nuclei iii.)C o-localization ii.) dsRed-MMGL
CARP
COMMD4
ENO1
ENO3
Figure 4 3D co-localization of MMGL and its respective preys identified in the Y2H library screen.R e p r e s e n t a t i v ei m a g e so fl i v ec e l l
fluorescence microscopy showing co-localization of MMGL and the putative interactors identified in the Y2H library screen in differentiated
H9C2 cardiac myocytes. (i) Individual GFP-tagged putative library screen interactors are seen as green fluorescence, as indicated by labels to the
left of the row. (ii) dsRed-tagged MMGL expression in the same cell(s) are shown are red fluorescence. (iii) Co-localization of interactors and
MMGL within these cell(s), generated from 3D vertical Z-stack images, are shown as yellow fluorescence. (iv) Overlay of images A-C with Hoechst
H-33342 labelling of the nuclei (blue) for orientation purposes. The presence of yellow staining in each of the images in (iii) indicates that each
of the respective preys colocalize with MMGL in differentiated H9C2 cardiomyocytes. Scale bar: 0.02 mm.
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Figure 5 Co-localization increases between MMGL and PKA target upon b-adrenergic stimulation. A.R e p r e s e n t a t i v ei m a g eo fl i v ec e l l
fluorescence microscopy showing co-localization of cTNI and MMGL isoform 4. Each panel represents a single frame of the 25 images that were
captured for the vertical Z-stack. The first four panels show a single colour channel, while the image in the last panel shows an overlay of the
four colour channels used. Column (iii) shows co-localization (yellow fluorescence) between dsRed-cTNI and YFP-MMGL, while column (iv) shows
cardiac actin, a marker of the sarcomeric region. Scale bar: 0.02 mm. B. Representative image of live cell fluorescence microscopy showing that
co-localization of MMGL isoform 4 and cTNI increases under adrenergic stress. Each panel represents a single frame of the 25 images that were
captured for the vertical Z-stack. Each of the first three columns shows a single colour channel, while the image in the last column shows an
overlay of the four colour channels used. Column iii shows co-localization (yellow fluorescence) between dsRed-MMGL and GFP-cTNI in the
absence (-isopro) and presence (+isopro) of the beta-adrenergic agonist, isoproterenol. The increase in intensity of yellow fluorescence in the
second row demonstrates that co-localization levels of MMGL and cTNI had increased ten minutes after the addition of isoproterenol. Scale bar:
0.02 mm. C. Quantification of co-localization shown in B shows that co-localization increased significantly (± SEM, *p < 0.05, n = 6) after the
addition of isoproterenol. Change in co-localization was calculated using the CellR software and presented as a false colour image and percent
co-localization as described by Loos et al., 2008 [29]. Abbreviations: isopro = isoproterenol.
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Page 8 of 15context of siRNA-mediated MMGL knockdown. Typi-
cally, interference with AKAP-functioning is commonly
more noticeable on the target protein only after adre-
nergic stimulation [16], thus we also tested the effect of
MMGL knockdown in the presence of adrenergic stimu-
lation. Of four siRNAs tested, Rn_RGD:708410_3_HP
siRNA (MMGL 3) (Qiagen) was found to provide opti-
mal knockdown of MMGL (80%) in H9C2 cells (Figure
7A); thus MMGL 3 siRNA was used in subsequent
experiments to silence MMGL gene expression.
Using Western blots of 2-dimensional IEF gels, we
found that similar amounts of the mono- and dipho-
sphorylated forms of cMyBPC were expressed in
untreated H9C2 cells, while lesser amounts of the un-
and trisphosphorylated forms, relative to the other iso-
forms, were present (Figure 7Bi, Ci). When these cells
were exposed to increased CaCl2 and isoproterenol, to
activate CaMK and PKA such that maximum phosphor-
ylation of the MyBPC-motif is likely[7], the relative
amount of the trisphosphorylated form increases mark-
edly, while the relative amount of unphosphorylated
cMyBPC decreased (Figure 7Bii, Cii). In untreated cells
lacking MMGL, all four forms of cMyBPC are present,
with amounts of mono- and diphosphorylated forms
similar and exceeding the amounts of un- and trispho-
sphorylated forms, similar to what was seen with
untreated, wild-type cells. However, adrenergic stimula-
tion in the presence of MMGLk n o c k d o w nr e s u l t e di n
very low expression of all isoforms (Figure 7Biv, Civ).
This finding is compatible with previous findings of an
inverse relationship between phosphorylation of
cMyBPC and its proteolytic degradation, suggesting that
phosphorylated cMyBPC is protected against proteolytic
cleavage, whereas absence of phosphorylation results in
increased degradation of the protein and reduced levels
of cMyBPC in the cell [17,18].
Discussion
Myomegalin has been characterized as a protein with
the properties of a scaffold or structural protein that is
expressed at high levels in skeletal and cardiac tissue,
suggesting an important function in muscle, and which
interacts with a cAMP-specific phosphodiesterase [13].
However, the precise function and interactions of this
protein, and its five isoforms, have been largely
unknown. We here describe how the smallest MMGL
isoform, isoform 4, binds to known and predicted PKA
targets in the cardiac myocyte, including some sarco-
meric proteins, viz. cMyBPC, cTNI, ENO1, ENO3,
C A R Pa n dC O M M D 4( T a b l e s1a n d2 ) .M o r e o v e r ,w e
show that MMGL isoform 4 interacts with two regula-
tory subunits of PKA (Figure 3). Together these results
describe MMGL isoform 4 as a novel sarcomeric AKAP,
which, like mAKAP [14], is involved in assembling a
PKA/PDE cAMP signalling module.
In addition to interacting with both types of regulatory
subunits, viz. RI and RII, which qualifies MMGL isoform 4
as a dual-specific AKAP [11,19]. MMGL also meets the
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Figure 6 In vivo co-immunoprecipitation of MMGL and its
respective preys identified in the Y2H library screen. Western
blots supporting the co-localization data in Figures 4 and 5.
Antibodies used in immunoprecipitation (IP) and Western Blot (WB)
are shown above each lane. Endogenous CARP (i), ENO1 (ii), ENO3 (iii)
and cTNI (iv) immunoprecipitated exogenous dsRed-/YFP-MMGL in
vivo in lysates of ds-Red-/YFP-MMGL transfected, differentiated H9C2
cardiomyocytes, while GFP-COMMD4 immunoprecipitated dsRed-
MMGL in differentiated H9C2 cardiomyocytes transfected with both
GFP-COMMD4 and dsRed-MMGL. Conversely, dsRed- or YFP-MMGL
immunoprecipitated endogenous CARP (i), ENO1 (ii), ENO3 (iii) and
cTNI (iv) in lysates of ds-Red- or YFP-MMGL transfected, differentiated
H9C2 cardiomyocytes, while dsRed-MMGL also immunoprecipitated
GFP-COMMD4. The dsRed antibody is directed against the dsRed-
MMGL fusion protein, while the JL-8 antibody is directed against the
YFP/GFP fusion proteins. The clear protein G control lanes show that
these precipitations are not spurious, but are the result of physical
association between the relevant proteins. Similar clear lanes were
obtained when the HA antibody was used in negative control
immunoprecipitation reactions (data not shown). Abbreviations: Prot
G = protein G control; JL8 = antibody directed against YFP-tagged
proteins, dsR = antibody directed against dsRed-tagged proteins, as
described above.
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Figure 7 siRNA-mediated knockdown of MMGL leads to reduced levels of cMyBPC phosphorylation under adrenergic stimulation. A.
Graph demonstrating that real-time quantification of MMGL cDNA transcribed from RNA extracted from cells transfected with either a non-
silencing control or a particular MMGL siRNA. Pde4dip Rn_RGD:708410_3_HP (MMGL 3) resulted in optimal knockdown of MMGL (80%). B.
Western blots of 2-dimensional IEF gels showing the expression of the four phosphorylation isoforms of GFP-cMyBPC in H9C2 cells (i) under
non-stimulated conditions; (ii) under adrenergic stimulation, (iii) under non-stimulated conditions in the absence of MMGL (i.e. with MMGL
knock-down) and (iv) under adrenergic stimulation in the absence of MMGL. C. Quantification of cMyBPC isoforms in the autoradiographs of the
2-dimensional IEF gels shown in (B), graphing the levels of the four phosphorylation isoforms (0 = unphosphorylated; 1 = monophosphorylated,
2 = diphosphorylated, 3 = trisphosphorylated). B and C(i) show that under non-stimulated conditions, levels of the mono- and diphosphorylated
forms are similar and increased compared to the trisphosphorylated form. B and C(ii) show that under adrenergic stimulation, there is a relative
increase in the trisphosphorylated form of cMyBPC and reduction of the non-phosphorylated form. B and C (iii) show that under non-stimulated
conditions, ratios of the four forms of cMyBPC are similar to that in wild-type cells. B and C(iv) show that, upon adrenergic stress, knock-down of
MMGL leads to a reduction in the levels of all cMyBPC phosphorylation forms. Abbreviations: JL8 = antibody directed against GFP-MyBPC.
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fying its interaction with its proposed binding partners, we
demonstrate that the targeting domains contained within
the proposed AKAP participates in protein-protein inter-
actions [11]. Further, it has previously been shown that
MMGL is a phosphodiesterase 4D-interacting protein
[13], thus, it meets the criterion for being able to coordi-
nate multiple signalling pathways by anchoring additional
signalling enzymes [11,20]. Lastly, we have shown in other
Y2H screens that cMyBPC also binds to COMMD4
(unpublished results), here shown to be a MMGL interac-
tor, while COMMD4 itself also binds to ENO1 and SNX3
(unpublished results). This strongly suggests that MMGL
is part of a larger, multiprotein unit [11,20], and that
MMGL isoform 4 may function as a vital link in signaling
between upstream activators and numerous downstream
targets [21].
Co-compartmentalization of both PKA and PDE4D is
crucial for maintaining specificity of adrenergic signal-
ing, and for maintaining contractility in cardiac cells
[16]. We here established an important and novel link
between PKA and PDE4D co-compartmentalization at
the sarcomere level, and cMyBPC phosphorylation, and
hence, regulation of cardiac contraction. The mechan-
ism of docking of PKA to cMyBPC for phosphorylation
of the MyBPC motif has previously not been elucidated;
this study strongly suggests that MMGL isoform 4
anchors PKA to the N-terminal region, viz. C1-C2, of
cMyBPC. The interaction between MMGL isoform 4,
PKA, PDE4D and the N-terminal region of cMyBPC
therefore sheds light on how second messenger
responses are regulated in this particular part of the
sarcomere.
We also found that b-adrenergic stimulation led to
greater co-localization of myomegalin with both
cMyBPC and cTNI in live cardiomyocytes, as evidenced
b yt h ei n c r e a s ei ny e l l o ws t a ining during fluorescence
microscopy in Figures 1 &5, respectively. Thus, although
MMGL is apparently present within the sarcomere
under normal conditions, this implies that under adre-
nergic stimulation, and consequential increased intracel-
lular levels of cAMP, PKA is dynamically recruited by
MMGL isoform 4 to distinct sarcomeric locations. This
translocation of MMGL to the sarcomeric region is
therefore compatible with a mechanism that would lead
to increased phosphorylation of cMyBPC and cTNI,
which is known to form part of the cardiac cellular
stress response that leads to increased cardiac contrac-
tion [22]. Furthermore, given MMGL’sk n o w ni n t e r a c -
tion with PDE4D [13], the mechanism for termination
of the second messenger response, by degrading cAMP,
would also be on site; lower levels of cAMP may then
cause this multiprotein complex to dissociate again.
The knockdown studies of MMGL further suggests
t h a tM M G Ln o to n l ya c t sa sa nA K A Pa tt h eM y B P C
motif, but by implication plays a role in cardioprotection
during adrenergic signaling. Although, in the presence
of MMGL, all phosphorylation isoforms of cMyBPC are
expressed well in H9C2 cells, and the level of the tri-
sphosphorylated cMyBPC is increased in such cells
under conditions of b-adrenergic stimulation as is to be
expected, knockdown of MMGL under adrenergic con-
ditions dramatically reduced cMyBPC expression (Figure
7). The latter finding suggests that when MMGL expres-
sion is reduced, cMyBPC phosphorylation is hindered,
rendering the protein vulnerable to cleavage by pro-
teases and reducing cMyBPC protein levels in the cell,
as described by others [17,18,23]. Typically, annulment
of the effect of an AKAP is commonly more noticeable
on the target protein only after adrenergic stimulation:
for instance, the studies of McConnell et al. (2009) [24]
and Fink et al. (2001) [16] showed no significant differ-
ence in the level of phosphorylation of key cardiac pro-
teins between wild-type cardiomyocytes and those in
which AKAP function had been impaired with the Ht31
peptide. However, upon isoproterenol stimulation, dra-
matically decreased levels of PKA phosphorylation of all
these proteins was observed in Ht31-transfected cells
compared to isoproterenol-stimulated wild-type cells.
Fink et al. (2001) [16] also demonstrated that AKAPs
regulate phosphorylation of these PKA targets, including
cTNI and cMyBPC, in response to b-adrenergic stimula-
tion, although it has been unknown which AKAP/s are
responsible for the phosphorylation of these two pro-
teins up until our study. Thus, it appears that MMGL is
an essential part in the b-adrenergic pathway leading to
trisphosphorylation of cMyBPC and protection of the
protein against degradation and normal sarcomeric
integrity, which in turn is essential for normal physiolo-
gical cardiac function, as well as cardioprotection during
ischemia-reperfusion injury [25].
The subcellular localization and functions of some of
the putative PKA targets identified via the Y2H library
screen suggest that MMGL may act as AKAP in regions
outside the sarcomere as well. Although some of the
identified interactions, such as those with cMyBPC and
cTNI, certainly occur within the sarcomere, associations
with the other identified interactors (Table 2) do not
necessarily occur within the sarcomere, nor do they
necessarily all occur concurrently. In fact, a multiprotein
subunit in the sarcomere consisting simultaneously of
all identified MMGL-ligands would most likely sterically
hinder crossbridge formation, and is therefore improb-
able. However, interaction of MMGL with proteins such
as COMMD4, CARP, ENO1 and ENO3 may facilitate
control of efficient PKA phosphorylation of these
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tion of these proteins may thus be regulated.
Although this study prioritized investigation of the
interaction between the N-terminal of cMyBPC and
MMGL, the other putative interactions of this region of
cMyBPC should be further explored. The absence of
cMyBPC as a prey in the MMGL Y2H library screen is
most likely explained by the known absence of cDNAs
representing the N-terminals of large proteins in oligo
dT-primed libraries, while the absence of PRKAR1A
and PRKAR2A may relate to the stringency of selection
during heterologous bait-matings during this Y2H
screen [26].
Interaction between myomegalin, PKA and cMyBPC
or cTNI is also relevant to understanding of HCM
patho-aetiology, as both of the latter proteins cause
HCM when defective. It is known that point mutations
in the C1-C2 region and in the MyBPC motif lead to
HCM [3,27]; a potential mechanism for this may be
involve disruption of binding between MMGL and
cMyBPC. Such disruption would have consequences for
PKA-phosphorylation of the cMyBPC motif (with impli-
cations for regulation of cardiac contractility), implying
a poison-peptide mechanism underlying disease, as well
as maintenance of sufficient cMyBPC levels within the
sarcomere, particularly under conditions of adrenergic
stress, implying a haplo-insufficiency mechanism. Point
mutations in cTNI may have a similar patho-aetiology.
It could be further speculated that, mutations in
MMGL could similarly lead to inadequate binding of
PKA and/or its sarcomeric partners, which might affect
cMyBPC or cTNI phosphorylation and hence affect
adaptation of cardiac contractility to adrenergic stimula-
tion. Future studies could therefore consider MMGL as
either a candidate causal gene or a potential modifier
gene for HCM.
Conclusions
This study shows that myomegalin isoform 4 is a novel
sarcomeric AKAP, which forms part of a multiprotein
complex that functions in cAMP signalling. It is particu-
larly relevant to phosphorylation of cMyBPC and cTNI,
and therefore, is of significance in the regulation of car-
diac contractility in both health and disease.
Methods
Plasmid constructs
Y2H constructs
T h er e g i o no fM Y B P C 3e n c o d i n gd o m a i n sC 1 - C 2w a s
PCR-amplified from a MYBPC3 cDNA clone (kind gift
of Prof Hugh Watkins, Oxford University). PCR-based
site-directed mutagenesis, as previously described by
Elliott et al. [28], was then used to generate a PCR frag-
ment representing domains C1-C2 in which the codons
for serines within all three phosphorylation sites of the
cMyBPC motif were mutated to encode glutamic acids
to mimic the trisphosphorylated state (PPP). The full-
length cDNA from MMGL isoform 4 was amplified
from a commercial construct, in vector pdEYFP-C1
(imaGenes GmbH). These fragments were individually
cloned into the NdeIa n dEcoRI restriction sites in-
frame with GAL4BD in the Y2H bait yeast expression
vector pGBKT7 (Clontech) for use in the respective
Y2H library screens or in Y2H-based direct protein-pro-
tein experiments.
The cDNA of the two PKA regulatory isoforms
(PRKAR1A and PRKAR2A) were PCR amplified from a
cardiac cDNA library (Clontech). These fragments were
cloned into the BamHI and XhoI restriction sites or the
NcoIa n dBamHI sites, respectively, of the Y2H prey
vector pACT2 (Clontech).
Integrity of insert sequences, reading frame and clon-
ing sites were verified by means of bi-directional
sequencing, after which pGBKT7-PPP and pGBKT7-
MMGL were transformed into S. cerevisiae strain
AH109, and pACT2-R1A and pACT2-R2A into strain
Y187 (Clontech).
Constructs used for verification analyses
The cDNAs from the putative interactors of MMGL iso-
form 4 identified in the Y2H library screen viz. TNNI3,
CARP, COMMD4, ENO1 and, ENO3,a sw e l la s
PRKAR1A and PRKAR2A, were PCR amplified and
cloned into the pGFP2-C1 fluorescent vector (BD
Bioscience). MMGL was further subcloned from the
pGBKT7-MMGL construct into the pDs-Red-C1 vector
(dsRed-MMGL) (BD Bioscience). The integrity of the
cloning sites, reading frames and all interactor
sequences were verified by bi-directional sequencing.
These constructs were subsequently used in 3D in vivo
co-localization and in vivo co-immunoprecipitation
analyses.
Y2H library screening
A S. cerevisciae Y187 pre-transformed human MATCH-
MAKER™ cardiac cDNA library constructed in pACT2
(BD Bioscience) was mated with the AH109 strain trans-
formed with pGBKT7-PPP and the library screen per-
formed according to manufacturer’s instructions. Clones
that expressed all three reporter genes, HIS3, ADE2, and
MEL1, were further analyzed. An interaction-specificity
test was used to identify preys that did not activate
reporter genes in the presence of the following heterolo-
gous baits: pGBKT7-C5 (encoding Igl domain C5 of
cMyBPC), pGBKT7-53 (encoding murine p53) and
unrecombined pGBKT7. Prey plasmids interacting speci-
fically with PPP were sequencedu s i n gav e c t o rs p e c i f i c
primer, and in-frame ORF sequences analyzed via
BLASTN and BLASTP http://ncbi.nlm.nih.gov/blast to
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were used to prioritize putative ligands according to
function and subcellular localization. A Y2H library
screen with pGBKT7-MMGL was subsequently similarly
performed.
Direct Y2H protein-protein interaction assay
pGBKT7-MMGL in yeast strain AH109 was mated indi-
vidually with pACT2-R1A and pACT2-R2A in yeast
strain Y187 to determine whether the PKA regulatory
subunits interacts directly with MMGL. A single colony
of pGBKT7-MMGL in AH109 was taken from appropri-
ate selection plates and suspended with a single colony
of pACT2-R1A or -R2A in YPDA media overnight. Mat-
ing mixes were plated onto solid growth medium lack-
ing leucine (Leu) and tryptophan (Trp). Following an
incubation period of four days, the colonies on each
plate were transferred to medium lacking Leu, Trp and
histidine (His), and incubated five days. Surviving colo-
nies were finally transferred to medium lacking Leu,
Trp, His and adenine (Ade) and growth was assessed on
day 4 and 7. Control matings were included those of
pGBKT7-MMGL with pACT2-cTNI(+), pACT2-TUSC4
(-) and empty pACT2(-).
Antibodies
Anti-HA, anti-Myc and anti-CARP antibodies were pur-
chased from Santa Cruz Biotechnology. Living colours™
anti-dsRed (directed against dsRed-tagged proteins) and
JL-8 (directed against GFP and YFP-tagged proteins)
antibodies were purchased from Clontech and anti-b-
actin antibody from Cell Signaling Technology. Anti-
ENO1, -ENO3, -PRKAR1A, -PRKAR2A and -cTNI anti-
bodies were purchased from Abnova.
Cell culture and transfection
H9C2 cells were maintained at 37°C and 5% CO2 in
Dulbecco’s modified Eagle’s medium, supplemented with
10% fetal bovine serum, 100 μg/ml penicillin and 100
μg/ml streptomycin. For in vivo co-immunoprecipita-
tion, approximately 4 million H9C2 cells were seeded
per 135 mm petri dish, and were transfected once 70-
80% confluency was reached. Genejuice
® (Novagen) was
used for transfections according to manufacturer’s
instructions. For 3D in vivo co-localization, approxi-
mately 20 000 - 30 000 H9C2 cells were seeded per well
in 8-well borosilicate coverglass chambers (Nunc), and
transfected after 70-80% confluency have been reached
using Lipofectamine™ (Invitrogen) according to manu-
facturer’s recommendations. Cells were differentiated
into myotubes 24 h after transfection by changing the
growth media to differentiation media (Dulbecco’s mod-
ified Eagle’s medium, 1% horse serum, 100 μg/ml peni-
cillin and 100 μg/ml streptomycin). Fresh differentiation
media was added every 48 h until cells were fully
differentiated.
Three-dimensional in vivo co-localization
Prior to image acquisition, the differentiation media was
removed from the co-transfected, differentiated H9C2
cells and replaced with culture media containing a 1:200
dilution of Hoechst H-33342 nucleic acid stain (Sigma).
Cells in three wells co-transfected with GFP-MyBPC/
dsRed-MMGL were photographed using an Olympus IX
81 motorised inverted microscope (Olympus); after
photography, cells were treated with 0.1 μM isoprotere-
nol in order to stimulate phosphorylation of the MyBPC
motif [7] and the same cells photographed again, to
monitor changes in co-localization upon adrenergic sti-
mulation. CellR software was used to perform image
analysis. Z-stacks were done in order to co-localize the
tagged proteins in three dimensions. Double-labelled
images, utilizing the co-transfected samples, were
obtained at different focal planes which were processed
by the CellR software to determine co-localization. A
60X oil immersion objective was used to collect image
stacks at 0.26 μm intervals in the plane. Subsequently,
each co-localized image was created from the average of
25 frames. Change in co-localization was calculated
using the CellR software and presented as a false colour
image and percent co-localization as described by Loos
et al., 2008 [29]. Changes in co-localization of MMGL
isoform 4 and cTNI were obtained in a similar manner.
In vitro protein transcription and translation
The cDNA encoding the native as well as the trispho-
sphorylated mimic of the C1-C2 region of cMyBPC and
the full-length MMGL isoform 4 cDNA were PCR
amplified to generate fragments that incorporates the
T7 promoter and Myc- or HA-epitope tags, respectively.
The TnT Quick Coupled Transcription/Translation Sys-
tem (Promega) was then used to transcribe and translate
these PCR products into Met-35S-radiolabelled proteins,
according to manufacturer’s instructions.
In vitro co-immunoprecipitation
Five microlitres of the respective 35S-labelled HA-
MMGL and Myc-C1-C2 were mixed and incubated for
1 h at room temperature. One microlitre of anti-HA or
anti-Myc antibody (5 μg / m l )w a sa d d e df o l l o w e db y
incubation of 1 h. Ten microlitres of pre-washed protein
G agarose (Kirkegaard & Perry Laboratories) were sub-
sequently added, together with 135 μl Co-IP buffer [5
mM phosphate-buffered saline (PBS), 5 μg/ml aprotinin,
0.5 mM PMSF, 100 mM DTT, 1% Tween-20]. Incuba-
tion of 1 h at 4°C followed on a rotating device. Centri-
fugation followed for 30 s at 3000 g,a f t e rw h i c ht h e
pellet was washed five times with Tris-buffered saline
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NaCl, 1% Tween-20]. Single immunoprecipitations were
performed in the same way, using the same volumes of
either bait or prey transcripts as were used in the co-
immunoprecipitation reactions. Samples were electro-
phoresed on a 20% SDS-polyacrylamide gel, and protein
bands were detected by autoradiography.
In vivo co-immunoprecipitation
H9C2 cells transfected with the appropriate constructs
were harvested 48 h following transfection, centrifuged
at 3000 rpm for 3 min and the pellet washed with PBS.
Two hundred microlitres of passive lysis buffer (PLB)
[0.5 M EDTA, 1 M NaVO4, 10 mM Nappi, 1 M
HEPES, 5 M NaCl, 1% TritonX, protease inhibitors and
phenylmethylsulfonyl fluoride (PMSF)] was added to
each sample. Samples were then incubated on ice for 30
min followed by centrifugation at 14000 rpm and the
supernatants collected. Lysate concentration was deter-
mined via a Bradford assay, and the volumes equalized
to 200 μl by adding PLB containing protease inhibitors
and PMSF with a final concentration of 200 μg/μl.
Lysates were pre-cleared by adding 20 μlP r o t e i nG
agarose beads (KPL) and incubating samples at 4°C for
2 h on a rotating device. Fluorescent-tagged or endogen-
ous proteins were immunoprecipitated from lysates
using 1-2 μg of the appropriate antibody, as indicated in
Figure 2c and 5. Following overnight incubation, 60 μl
of protein G agarose beads was added to each sample,
and incubated at 4°C for 2 h on a rotating device. After-
wards, immunoprecipitates were washed 5X in cold PLB
containing protease inhibitors and PMSF, followed by
resuspension in SDS loading buffer, and boiling prior to
SDS-PAGE and subsequent Western blotting. Negative
controls included samples inw h i c hp r o t e i nGo n l yw a s
used in the absence of antibody, samples in which the
HA-antibody was used as a negative control-antibody,
and samples that had not been transfected with the
dsRed-MMGL construct.
RNA interference
The effect of siRNA transfection on myomegalin mRNA
expression using different PDE4DIP siRNAs (Qiagen)
was determined and optimized by a 2-step Q-RT-PCR
using the Corbett Rotorgene system as follows: Approxi-
mately 4 × 10
4 H9C2 cells were seeded per well of an 8-
well chamber slide, and siRNA transfected when cells
reached 50-60% confluency, using HiPerFect transfection
reagent (Qiagen) as per manufacturer’s instructions.
Total RNA extraction followed after 24 hours using the
RNeasy Plus Mini kit (Qiagen) as per manufacturer’s
instructions. cDNA was subsequently transcribed using
the Quantitect Reverse Transcription kit (Qiagen) as per
manufacturer’s instructions. The Quantifast SYBR green
PCR kit (Qiagen) was then used to perform a real-time
quantification of cDNA transcribed from the extracted
RNA with or without non-silencing control (NSC) or
PDE4DIP siRNAs. PDE4DIP levels were quantified with
reference to three rodent reference genes (transferring
receptor - TRFR, glyceraldehydes-3-phosphate dehydro-
genase - GAPDH and heat shock protein 1b- Hsp1b)
selected from a panel of 6 commonly used housekeeping
genes.
The Genomewide designed non-validated
Rn_RGD:708410_3_HP siRNA (Qiagen) resulted in the
lowest MMGL gene expression quantification levels, and
was used in subsequent experiments. Confluent H9C2
cells were transfected with GFP-tagged cMyBPC using
Genejuice
® (Novagen). These cells were then transfected
after 24 h with 10 nM PDE4DIP Rn_RGD:708410_3_HP
siRNA using HiPerFect Transfection Reagent (Qiagen);
control cells were not transfected with siRNA. For adre-
nergic stimulated cells, cells were treated with 65 mM
CaCl2 for 10 min at 24 h post-transfection, followed by
a0 . 1μM isoproterenol treatment for another 10 min.
All cells were then lysed (as done for in vivo co-immu-
noprecipitation) and concentrations determined via
Bradford assays, and all volumes equalized to 200 μlb y
adding PLB containing protease inhibitors and PMSF
with a final concentration of 200 μg/μl. A non-denatur-
ing immunoprecipitation of GFP-cMyBPC from the
lysate followed using 1 μg of the JL-8 antibody with the
Dynabeads
® Protein G and DynaMag™-2 system (Invi-
trogen) as per manufacturer’s instructions. Isoelectric
focusing of the GFP-cMyBPC immunoprecipitates fol-
lowed to separate the four possible phosphorylation iso-
forms of cMyBPC.
Isoelectric focusing
For the first dimension separation, the GFP-tagged
cMyBPC immunoprecipitates were suspended in Ready-
Prep 2-D Rehydration buffer 1 (Bio-Rad) containing
Bio-lite pH 3-10 buffer (Bio-Rad) to a final volume of
200 μl. The protein/rehydration buffer mix was then
applied to a pH 4-7 (11 cm) immobilized pH gradient
(IPG) strip (Bio-Rad). Rehydration of the strip followed
for 12 hours at room temperature. Afterwards, IEF was
done under the following conditions: 8000 V for 20
min, 8000 V for 2 hours and 8000 V for 40 000 V hours
at 21°C (Protean IEF Cell, Bio-Rad). Strips were stored
at -80°C after IEF until required.
For 2-dimensional gel electrophoresis (2-DE), IPG
strips were equilibrated by incubating the strips in equi-
libration buffer (0.375 M tris-HCl, 6 M urea, 20% gly-
cerol, 2%, SDS) containing DTT( S i g m a - A l d r i c h )f o r1 5
min and then in equilibration buffer containing iodoace-
tamide (Sigma-Aldrich) for 15 min shaking at room
temperature. Following equilibration, the IPG strips
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cast gel (Bio-Rad) and sealed with 0.5% agarose (Bio-
Rad). Electrophoresis of the second dimension separa-
tion was done under constant voltage (200 V) for 1-2
hours in 5% XT-MOPS running buffer (Bio-Rad). Gels
were then transferred to a nitrocellulose membrane and
subsequently western blotted with the JL-8 antibody.
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